Exploring the Extracellular Vesicle MicroRNA Expression Repertoire in Patients with Rheumatoid Arthritis and Ankylosing Spondylitis Treated with TNF Inhibitors
Rheumatoid arthritis (RA) and ankylosing spondylitis (AS) belong to the most common inflammatory rheumatic diseases. MicroRNAs (miRNAs) are small 18–22 RNA molecules that function as posttranscriptional regulators. They are abundantly present within extracellular vesicles (EVs), small intercellular...
Main Authors: | , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Limited
2021-01-01
|
Series: | Disease Markers |
Online Access: | http://dx.doi.org/10.1155/2021/2924935 |
id |
doaj-a4511cd5df2a4c1186739e67a902f029 |
---|---|
record_format |
Article |
spelling |
doaj-a4511cd5df2a4c1186739e67a902f0292021-10-11T00:39:14ZengHindawi LimitedDisease Markers1875-86302021-01-01202110.1155/2021/2924935Exploring the Extracellular Vesicle MicroRNA Expression Repertoire in Patients with Rheumatoid Arthritis and Ankylosing Spondylitis Treated with TNF InhibitorsJoanna Wielińska0Rachel E. Crossland1Piotr Łacina2Jerzy Świerkot3Bartosz Bugaj4Anne M. Dickinson5Katarzyna Bogunia-Kubik6Laboratory of Clinical Immunogenetics and PharmacogeneticsTranslational and Clinical Research InstituteLaboratory of Clinical Immunogenetics and PharmacogeneticsDepartment of Rheumatology and Internal MedicineDepartment of Rheumatology and Internal MedicineTranslational and Clinical Research InstituteLaboratory of Clinical Immunogenetics and PharmacogeneticsRheumatoid arthritis (RA) and ankylosing spondylitis (AS) belong to the most common inflammatory rheumatic diseases. MicroRNAs (miRNAs) are small 18–22 RNA molecules that function as posttranscriptional regulators. They are abundantly present within extracellular vesicles (EVs), small intercellular communication vesicles that can be found in bodily fluids and that have key functions in pathological and physiological pathways. Recently, EVs have gained much interest because of their diagnostic and therapeutic potential. Using NanoString profiling technology, the miRNA repertoire of serum EVs was determined and compared in RA and AS patients before and after anti-TNF therapy to assess its potential use as a diagnostic and prognostic biomarker. Furthermore, possible functional effects of those miRNAs that were characterized by the most significant expression changes were evaluated using in silico prediction algorithms. The analysis revealed a unique profile of differentially expressed miRNAs in RA and AS patient serum EVs. We identified 12 miRNAs whose expression profiles enabled differentiation between RA and AS patients before induction of anti-TNF treatment, as well as 4 and 14 miRNAs whose repertoires were significantly changed during the treatment in RA and AS patients, respectively. In conclusion, our findings suggest that extracellular vesicle miRNAs could be used as potential biomarkers associated with RA and AS response to biological treatment.http://dx.doi.org/10.1155/2021/2924935 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Joanna Wielińska Rachel E. Crossland Piotr Łacina Jerzy Świerkot Bartosz Bugaj Anne M. Dickinson Katarzyna Bogunia-Kubik |
spellingShingle |
Joanna Wielińska Rachel E. Crossland Piotr Łacina Jerzy Świerkot Bartosz Bugaj Anne M. Dickinson Katarzyna Bogunia-Kubik Exploring the Extracellular Vesicle MicroRNA Expression Repertoire in Patients with Rheumatoid Arthritis and Ankylosing Spondylitis Treated with TNF Inhibitors Disease Markers |
author_facet |
Joanna Wielińska Rachel E. Crossland Piotr Łacina Jerzy Świerkot Bartosz Bugaj Anne M. Dickinson Katarzyna Bogunia-Kubik |
author_sort |
Joanna Wielińska |
title |
Exploring the Extracellular Vesicle MicroRNA Expression Repertoire in Patients with Rheumatoid Arthritis and Ankylosing Spondylitis Treated with TNF Inhibitors |
title_short |
Exploring the Extracellular Vesicle MicroRNA Expression Repertoire in Patients with Rheumatoid Arthritis and Ankylosing Spondylitis Treated with TNF Inhibitors |
title_full |
Exploring the Extracellular Vesicle MicroRNA Expression Repertoire in Patients with Rheumatoid Arthritis and Ankylosing Spondylitis Treated with TNF Inhibitors |
title_fullStr |
Exploring the Extracellular Vesicle MicroRNA Expression Repertoire in Patients with Rheumatoid Arthritis and Ankylosing Spondylitis Treated with TNF Inhibitors |
title_full_unstemmed |
Exploring the Extracellular Vesicle MicroRNA Expression Repertoire in Patients with Rheumatoid Arthritis and Ankylosing Spondylitis Treated with TNF Inhibitors |
title_sort |
exploring the extracellular vesicle microrna expression repertoire in patients with rheumatoid arthritis and ankylosing spondylitis treated with tnf inhibitors |
publisher |
Hindawi Limited |
series |
Disease Markers |
issn |
1875-8630 |
publishDate |
2021-01-01 |
description |
Rheumatoid arthritis (RA) and ankylosing spondylitis (AS) belong to the most common inflammatory rheumatic diseases. MicroRNAs (miRNAs) are small 18–22 RNA molecules that function as posttranscriptional regulators. They are abundantly present within extracellular vesicles (EVs), small intercellular communication vesicles that can be found in bodily fluids and that have key functions in pathological and physiological pathways. Recently, EVs have gained much interest because of their diagnostic and therapeutic potential. Using NanoString profiling technology, the miRNA repertoire of serum EVs was determined and compared in RA and AS patients before and after anti-TNF therapy to assess its potential use as a diagnostic and prognostic biomarker. Furthermore, possible functional effects of those miRNAs that were characterized by the most significant expression changes were evaluated using in silico prediction algorithms. The analysis revealed a unique profile of differentially expressed miRNAs in RA and AS patient serum EVs. We identified 12 miRNAs whose expression profiles enabled differentiation between RA and AS patients before induction of anti-TNF treatment, as well as 4 and 14 miRNAs whose repertoires were significantly changed during the treatment in RA and AS patients, respectively. In conclusion, our findings suggest that extracellular vesicle miRNAs could be used as potential biomarkers associated with RA and AS response to biological treatment. |
url |
http://dx.doi.org/10.1155/2021/2924935 |
work_keys_str_mv |
AT joannawielinska exploringtheextracellularvesiclemicrornaexpressionrepertoireinpatientswithrheumatoidarthritisandankylosingspondylitistreatedwithtnfinhibitors AT rachelecrossland exploringtheextracellularvesiclemicrornaexpressionrepertoireinpatientswithrheumatoidarthritisandankylosingspondylitistreatedwithtnfinhibitors AT piotrłacina exploringtheextracellularvesiclemicrornaexpressionrepertoireinpatientswithrheumatoidarthritisandankylosingspondylitistreatedwithtnfinhibitors AT jerzyswierkot exploringtheextracellularvesiclemicrornaexpressionrepertoireinpatientswithrheumatoidarthritisandankylosingspondylitistreatedwithtnfinhibitors AT bartoszbugaj exploringtheextracellularvesiclemicrornaexpressionrepertoireinpatientswithrheumatoidarthritisandankylosingspondylitistreatedwithtnfinhibitors AT annemdickinson exploringtheextracellularvesiclemicrornaexpressionrepertoireinpatientswithrheumatoidarthritisandankylosingspondylitistreatedwithtnfinhibitors AT katarzynaboguniakubik exploringtheextracellularvesiclemicrornaexpressionrepertoireinpatientswithrheumatoidarthritisandankylosingspondylitistreatedwithtnfinhibitors |
_version_ |
1716829214515134464 |